Dalbavancin
| Evidence Level: L1 | Predicted Indications: 10 |
Table of Contents
- Dalbavancin
- Dalbavancin: From Acute Bacterial Skin and Skin Structure Infections to Post-Bacterial Disorder
Dalbavancin: From Acute Bacterial Skin and Skin Structure Infections to Post-Bacterial Disorder
One-Sentence Summary
Dalbavancin is a long-acting lipoglycopeptide antibiotic internationally approved for Acute Bacterial Skin and Skin Structure Infections (ABSSSI) caused by susceptible Gram-positive organisms, but currently not marketed in Taiwan. The TxGNN model predicts it may be effective for Post-Bacterial Disorder — a broad disease node encompassing S. aureus bacteremia, infective endocarditis, and bone/joint infections beyond its approved ABSSSI indication — with 8 clinically active or completed trials supporting this direction, including a completed Phase 2b RCT in S. aureus bacteremia and an ongoing Phase 3 confirmatory trial.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Acute Bacterial Skin and Skin Structure Infections (ABSSSI) — not currently marketed in Taiwan |
| Predicted New Indication | Post-Bacterial Disorder |
| TxGNN Prediction Score | 99.76% |
| Evidence Level | L1 |
| Taiwan Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in this evidence pack. Based on known information, Dalbavancin is a lipoglycopeptide antibiotic with an exceptionally long plasma half-life of approximately 8–10 days — a pharmacokinetic property that fundamentally distinguishes it from conventional antibiotics. This allows once-weekly or single-dose intravenous administration, making it ideally suited for Outpatient Parenteral Antibiotic Therapy (OPAT). It exhibits concentration-dependent bactericidal activity against Gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and streptococcal species.
The “post-bacterial disorder” node in the TxGNN knowledge graph functions as a broad disease category that encompasses the full clinical spectrum of serious Gram-positive infections — from the approved ABSSSI indication to S. aureus bacteremia (SAB), complicated infective endocarditis, and osteomyelitis. The mechanistic continuity is strong: the same bactericidal efficacy against MRSA/MSSA that treats skin infections is directly applicable to bacteremia and endovascular infections. The key clinical innovation lies in the OPAT model — dalbavancin’s prolonged half-life compresses what would traditionally require 4–6 weeks of daily IV vancomycin into 1–2 administrations, dramatically reducing hospital days and catheter-related complication risks.
The translation from ABSSSI to bloodstream and deep-seated infections is not a speculative leap: the DOTS trial (NCT04775953, Phase 2b, n=200, completed) directly investigated dalbavancin for complicated SAB with right-sided infective endocarditis, and a Phase 3 confirmatory trial (NCT05117398, n=406) is actively recruiting for catheter-related SAB. This stepwise clinical development strongly validates what TxGNN identified through graph-based inference.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT04775953 | Phase 2b | Completed | 200 | DOTS trial: dalbavancin vs. standard of care for completed treatment of complicated S. aureus bacteremia or right-sided native valve infective endocarditis after bacteremia clearance; the most direct re-purposing evidence beyond approved indication |
| NCT05117398 | Phase 3 | Recruiting | 406 | Single-dose dalbavancin 1500 mg vs. 14-day standard antibiotic therapy for non-complicated catheter-related S. aureus bloodstream infections; primary endpoint at Day 30; key confirmatory Phase 3 following DOTS |
| NCT01431339 | Phase 3 | Completed | 739 | DISCOVER 1: dalbavancin vs. vancomycin/linezolid for ABSSSI; established safety and efficacy at 48–72 hours for Gram-positive skin infections including MRSA |
| NCT01339091 | Phase 3 | Completed | 573 | DISCOVER 2: replication of DISCOVER 1 across additional geographic regions; confirmed cross-regional consistency of Gram-positive efficacy as the co-pivotal registration trial |
| NCT02127970 | Phase 3 | Completed | 698 | Single-dose 1500 mg vs. two-dose regimen for ABSSSI; established non-inferiority of single-administration OPAT model that underpins all subsequent bloodstream infection strategies |
| NCT02814916 | Phase 3 | Completed | 199 | Pediatric ABSSSI (birth–17 years, open-label): safety and descriptive efficacy in children with suspected or proven Gram-positive infections including MRSA strains |
| NCT03233438 | Phase 4 | Completed | 91 | Critical pathway study: guideline-based patient selection + dalbavancin vs. usual care for ABSSSI; assessed real-world OPAT clinical feasibility and healthcare utilization outcomes |
| NCT04847921 | Phase 2/3 | Terminated | 11 | Simplified two-dose dalbavancin for severe Gram-positive infections in people who inject drugs; terminated early due to recruitment challenges (n=11 only), but conceptually validates OPAT re-purposing in adherence-challenged populations |
| NCT06810583 | Phase 1 | Recruiting | 29 | Dalbavancin-based prophylaxis in pediatric AML or relapsed ALL receiving myelosuppressive chemotherapy; evaluates bacteremia prevention in immunocompromised hosts with every-28-day dosing |
| NCT03941951 | N/A | Unknown | 900 | NEW_SAFE project (Andalusia, Spain): quasi-experimental optimization study of new antibiotics including dalbavancin across 14 hospitals; antibiotic stewardship background reference |
Literature Evidence
Currently no related literature available for the post-bacterial disorder indication.
Safety Considerations
Please refer to the SmPC for safety information.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The completed DOTS Phase 2b trial (n=200) directly demonstrates dalbavancin’s efficacy in S. aureus bacteremia — the most clinically impactful re-purposing target — and a Phase 3 confirmatory trial is actively enrolling, providing an evidence trajectory that, combined with the established ABSSSI pivotal trials, meets L1 criteria for the broader post-bacterial disorder category.
To proceed, the following is needed:
- Mechanism of action documentation (DrugBank API query pending — currently DG002 High severity gap)
- Taiwan TFDA prescribing information / safety section (currently DG001 Blocking severity gap; required before any S1 safety assessment can be initiated)
- Review of DOTS Phase 2b full publication results (NCT04775953) to assess primary and secondary clinical endpoint outcomes
- Evaluation of NCT05117398 Phase 3 interim data as it becomes available
- Pharmacokinetic-pharmacodynamic (PK/PD) target attainment modeling for bacteremia and deep-seated infection compartments
- Development of an OPAT safety monitoring protocol covering infusion-related reactions, hepatic function, and Clostridium difficile risk
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.